Worth reading
57In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
13.1
Year-on-year revenue growth (%)Wording
Conditional
How definitive the wording is.Contents of this document
Supplementary materials to the earnings reportFirst quarter of the fiscal year ending March 202710 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥6,729 million+13.1%
Operating profit¥855 million+48.4%
Ordinary income¥915 million+45.8%
Net income¥532 million +32.7%profit attributable to owners of the parent
Gross Profit Margin67.3 %
Operating profit margin12.7 %
Selling, general and administrative expenses¥3,670 million
Results for the three months of the current quarter
Net Sales
¥6,729 million
Operating profit
¥855 million
Ordinary income
¥915 million
Net income
¥532 million profit attributable to owners of the parent
Full-year earnings forecast
Net Sales
¥270 hundred million FY ending March 2027 plan
By segment
Water ionizers
¥100 100 million
Cartridges
¥60.6 100 million
Bottled water
¥62 100 million
Regenerative Medicine
¥32.4 100 million
Electrolyzed water dialysis
¥2 100 million
Other
¥13 100 million
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Change in operating profit
Impact of higher sales530
Impact of higher cost ratio-34
Impact of changes in sales mix-14
Increase in selling expenses-105
Increase in personnel expenses-34
Increase in advertising expenses-53
Other-8
New initiatives
- Investment in human capital to support business expansion
- Proactive promotion of research and development activities
- Investment in new businesses through M&A
- Strengthening IR activities and dialogue with shareholders
Key KPIsA metric the company considers important as a management benchmark.
Bottled water business sales mix
22.2 %
yoy_change_points4.1
Year-on-year change in group headcount
22 people
Actual ROE
8.5 %
Actual PBR
1.34 times
Segment results
DS Division (workplace sales)
Net Sales
¥1,513 million
Year on year against the same period last year+12.2%
HS Division (installation and referral sales)
Net Sales
¥378 million
Year on year against the same period last year+9.7%
SS Division (in-store event sales)
Net Sales
¥156 million
Year on year against the same period last year+11.8%
Operations Department (maintenance)
Net Sales
¥86 million
Year on year against the same period last year+1.0%
Replacement Department
Net Sales
¥128 million
Year on year against the same period last year+8.3%
Web Sales Department
Net Sales
¥121 million
Year on year against the same period last year+12.0%
MS Division (wholesale and OEM)
Net Sales
¥219 million
Year on year against the same period last year+0.1%
Total water ionizer sales
Net Sales
¥2,604 million
Year on year against the same period last year+10.1%
Cartridges
Net Sales
¥1,560 million
Year on year against the same period last year+7.4%
Guangzhou Duoning Health Technology Co., Ltd.
Net Sales
¥18 million
Year on year against the same period last year+51.5%
PT. SUPER WAHANA TEHNO (bottled water)
Net Sales
¥1,495 million
Year on year against the same period last year+39.2%
Other
Net Sales
¥305 million
Year on year against the same period last year+4.9%
Water Healthcare Business
Net Sales
¥5,984 million
Year on year against the same period last year+15.2%
Regenerative Medicine-Related Business
Net Sales
¥738 million
Year on year against the same period last year+3.6%
Electrolyzed Water Dialysis Business
Net Sales
¥6 million
Year on year against the same period last year-83.1%
Medical-related business
Net Sales
¥745 million
Year on year against the same period last year-1.0%
Medium-term management plan targets
Fiscal year ending March 2027
Net Sales
¥270 100 million
Fiscal year ending March 2028
Net Sales
¥310 100 million
Financial targets
ROE target
10 % or higher
Actual ROE
8.5 % as of March 2026
Cost of capital
8 %
Number of employees
Change during the period
22 people year on year
Annual Dividend
Forecast for the fiscal year ending March 2027
¥130 per share
Payout ratio
DOE
4 %
Acquisition of treasury shares
Fiscal year ending March 2026
Number of Shares
25 10,000 shares
| Item | Details |
|---|---|
| Document type | Supplementary materials to the earnings report |
| Fiscal Period Covered | First quarter of the fiscal year ending March 2027 |
| Net Sales | ¥6,729 million (YoY +13.1%) |
| Operating profit | ¥855 million (YoY +48.4%) |
| Ordinary income | ¥915 million (YoY +45.8%) |
| Net income | ¥532 million (profit attributable to owners of the parent) (YoY +32.7%) |
| Gross Profit Margin | 67.3 % |
| Operating profit margin | 12.7 % |
| Selling, general and administrative expenses | ¥3,670 million |
| Results for the three months of the current quarter | Net Sales ¥6,729 million / Operating profit ¥855 million / Ordinary income ¥915 million / Net income ¥532 million (profit attributable to owners of the parent) |
| Full-year earnings forecast | Net Sales ¥270 hundred million (FY ending March 2027 plan) / By segment Water ionizers ¥100 100 million / Cartridges ¥60.6 100 million / Bottled water ¥62 100 million / Regenerative Medicine ¥32.4 100 million / Electrolyzed water dialysis ¥2 100 million / Other ¥13 100 million |
| Segment results | DS Division (workplace sales) Net Sales ¥1,513 million / yoy_pct 12.2 / HS Division (installation and referral sales) Net Sales ¥378 million / yoy_pct 9.7 / SS Division (in-store event sales) Net Sales ¥156 million / yoy_pct 11.8 / Operations Department (maintenance) Net Sales ¥86 million / yoy_pct 1 / Replacement Department Net Sales ¥128 million / yoy_pct 8.3 / Web Sales Department Net Sales ¥121 million / yoy_pct 12 / MS Division (wholesale and OEM) Net Sales ¥219 million / yoy_pct 0.1 / Total water ionizer sales Net Sales ¥2,604 million / yoy_pct 10.1 / Cartridges Net Sales ¥1,560 million / yoy_pct 7.4 / Guangzhou Duoning Health Technology Co., Ltd. Net Sales ¥18 million / yoy_pct 51.5 / PT. SUPER WAHANA TEHNO (bottled water) Net Sales ¥1,495 million / yoy_pct 39.2 / Other Net Sales ¥305 million / yoy_pct 4.9 / Water Healthcare Business Net Sales ¥5,984 million / yoy_pct 15.2 / Regenerative Medicine-Related Business Net Sales ¥738 million / yoy_pct 3.6 / Electrolyzed Water Dialysis Business Net Sales ¥6 million / yoy_pct -83.1 / Medical-related business Net Sales ¥745 million / yoy_pct -1 |
| Breakdown of Factors Affecting the Change | Change in operating profit Impact of higher sales 530 / Impact of higher cost ratio -34 / Impact of changes in sales mix -14 / Increase in selling expenses -105 / Increase in personnel expenses -34 / Increase in advertising expenses -53 / Other -8 |
| Key KPIs | Bottled water business sales mix 22.2 % / Year-on-year change in group headcount 22 people / Actual ROE 8.5 % / Actual PBR 1.34 times |
| Number of employees | Change during the period 22 people (year on year) / Number of Employees Not disclosed |
| Medium-term management plan targets | Fiscal year ending March 2027 Net Sales ¥270 100 million / Fiscal year ending March 2028 Net Sales ¥310 100 million |
| Financial targets | ROE target 10 % or higher / Actual ROE 8.5 % (as of March 2026) / Cost of capital 8 % |
| Annual Dividend | Forecast for the fiscal year ending March 2027 ¥130 per share |
| Payout ratio | DOE 4 % |
| Acquisition of treasury shares | Fiscal year ending March 2026 Number of Shares 25 10,000 shares / Amount Not disclosed / Period Not disclosed |
| New initiatives | Investment in human capital to support business expansion, Proactive promotion of research and development activities, Investment in new businesses through M&A, Strengthening IR activities and dialogue with shareholders |
Items this document does not state (10)
Progress against full-year forecastSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Higher sales in each business drove profit growth, while changes in the sales mix resulting from growth in the bottled water business, rising platinum prices for the electrode plates used in water ionizers, higher resin material prices resulting from rising crude oil prices, and increased investment in human capital to support business expansion were cited as factors affecting profit.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.